EADO 2022 | Treatment selection for stage III BRAF-mutant melanoma

Eva Muñoz Couselo, MD, PhD, Vall d’Hebrón Hospital, Barcelona, Spain, discusses treatment selection for patients with stage III BRAF-mutant melanoma. It remains unclear which treatment is best for patients due to a current lack of biomarkers and, as such, treatment decisions are based on clinical factors. Dr Couselo highlights two clinical trials that may aid in future treatment decision making for this patient population. The Phase III DREAMseq (NCT02224781) trial is comparing the efficacy and toxicity of the sequence of nivolumab/ipilimumab followed by dabrafenib/trametinib to the converse sequence in patients with untreated, metastatic BRAFV600-mutated melanoma. The Phase II SECOMBIT (NCT02631447) trial is investigating the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (encorafenib/binimetinib) in patients with BRAF mutated metastatic melanoma. This interview took place at the EADO 2022 congress.